NO20051469L - Immunstimulerende nukleinsyrer. - Google Patents

Immunstimulerende nukleinsyrer.

Info

Publication number: NO20051469L
Authority: NO; Norway
Prior art keywords: immune; nucleic acids; stimulating nucleic; stimulating; soft
Prior art date: 2002-08-19

Application number

NO20051469A

Other languages

English (en)

Norwegian (no)

Inventor

Eugen Uhlmann

Arthur M Krieg

Ulrike Samulowitz

Jorg Vollmer

Marion Jurk

Grayson Lipford

Robert Rankin

Original Assignee

Coley Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-19

Filing date

2005-03-18

Publication date

2005-05-19

2005-03-18 Application filed by Coley Pharm Gmbh filed Critical Coley Pharm Gmbh

2005-05-19 Publication of NO20051469L publication Critical patent/NO20051469L/no

Links

150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

NO20051469A 2002-08-19 2005-03-18 Immunstimulerende nukleinsyrer. NO20051469L (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US40482002P	2002-08-19	2002-08-19
US40447902P	2002-08-19	2002-08-19
US42970102P	2002-11-27	2002-11-27
US44737703P	2003-02-14	2003-02-14
PCT/US2003/025935 WO2004016805A2 (en)	2002-08-19	2003-08-19	Immunostimulatory nucleic acids

Publications (1)

Publication Number	Publication Date
NO20051469L true NO20051469L (no)	2005-05-19

Family

ID=31892263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051469A NO20051469L (no)	2002-08-19	2005-03-18	Immunstimulerende nukleinsyrer.

Country Status (27)

Country	Link
US (2)	US8283328B2 (pl)
EP (2)	EP2290078B1 (pl)
JP (2)	JP5414961B2 (pl)
KR (2)	KR20080011247A (pl)
AR (1)	AR040996A1 (pl)
AU (2)	AU2003259916B2 (pl)
BR (1)	BR0313414A (pl)
CA (1)	CA2493753C (pl)
DK (2)	DK1538904T3 (pl)
EC (1)	ECSP055687A (pl)
ES (2)	ES2634328T3 (pl)
HU (2)	HUE030347T2 (pl)
IL (1)	IL166376A (pl)
MA (1)	MA27468A1 (pl)
MX (1)	MXPA05002014A (pl)
NO (1)	NO20051469L (pl)
NZ (2)	NZ560722A (pl)
OA (1)	OA12906A (pl)
PE (2)	PE20040900A1 (pl)
PL (2)	PL232260B1 (pl)
PT (2)	PT2290078T (pl)
RS (1)	RS20050126A (pl)
SI (1)	SI2290078T1 (pl)
SV (1)	SV2008001602A (pl)
TW (1)	TW200412981A (pl)
UY (1)	UY27945A1 (pl)
WO (1)	WO2004016805A2 (pl)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
EP0855184A1 (en) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2289702C (en) *	1997-05-14	2008-02-19	Inex Pharmaceuticals Corp.	High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6218371B1 (en) *	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU760795B2 (en) *	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
DE60044236D1 (de) *	1999-02-17	2010-06-02	Csl Ltd	Immunogene komplexe und methoden in bezug auf diese
EP1176966B1 (en) *	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynucleotide and its use to induce an immune response
WO2001022972A2 (en) *	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Immunostimulatory nucleic acids
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en) *	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
EP1296714B1 (en) *	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
EP1366077B1 (en) *	2000-09-15	2011-05-25	Coley Pharmaceutical GmbH	PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
WO2002069369A2 (en) *	2000-12-08	2002-09-06	Coley Pharmaceutical Gmbh	Cpg-like nucleic acids and methods of use thereof
KR100985457B1 (ko) *	2001-06-21	2010-10-06	다이나박스 테크놀로지 코퍼레이션	키메라 면역조절 화합물 및 그것들의 사용 방법
EA007232B1 (ru) *	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
AU2002360278A1 (en) *	2001-10-12	2003-11-11	Coley Pharmaceutical Gmbh	Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003039595A2 (en) *	2001-11-07	2003-05-15	Inex Pharmaceuticals Corporation	Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
NZ535952A (en) *	2002-04-04	2009-01-31	Coley Pharm Gmbh	Immunostimulatory G,U-containing oligoribonucleotides
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) *	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
SG167667A1 (en) *	2002-07-03	2011-01-28	Coley Pharm Group Inc	Nucleic acid compositions for stimulating immune responses
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
NZ540098A (en) *	2002-10-29	2008-09-26	Coley Pharmaceutical Group Ltd	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) *	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
EP1608403A2 (en) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
KR20060012622A (ko) *	2003-05-16	2006-02-08	하이브리돈, 인코포레이티드	화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
US7410975B2 (en) *	2003-06-20	2008-08-12	Coley Pharmaceutical Group, Inc.	Small molecule toll-like receptor (TLR) antagonists
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
JP4989225B2 (ja) *	2003-09-25	2012-08-01	コーリーファーマシューティカルグループ，インコーポレイテッド	核酸親油性接合体
CA2542099A1 (en) *	2003-10-11	2005-04-21	Inex Pharmaceuticals Corporation	Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
NZ546275A (en) *	2003-10-30	2009-05-31	Coley Pharm Gmbh	C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
JP2007526253A (ja) *	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
JP2007531746A (ja) *	2004-04-02	2007-11-08	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｉｌ−１０応答を誘導するための免疫活性化核酸
WO2006080946A2 (en) *	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006091915A2 (en) *	2005-02-24	2006-08-31	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
EP1874325A2 (en) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Methods for treating infectious disease exacerbated asthma
AU2006241149A1 (en) *	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007008463A2 (en) *	2005-07-07	2007-01-18	Coley Pharmaceutical Group, Inc.	Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US20090214578A1 (en) *	2005-09-16	2009-08-27	Coley Pharmaceutical Gmbh	Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
KR20080047463A (ko) *	2005-09-16	2008-05-28	콜리 파마슈티칼 게엠베하	뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
WO2007062107A2 (en)	2005-11-25	2007-05-31	Coley Pharmaceutical Gmbh	Immunostimulatory oligoribonucleotides
EP1986664A4 (en) *	2006-02-01	2009-07-22	Eyegene Inc	COMPOSITION FOR THE TREATMENT OF CANCER WITH OLIGONUCLEOTIDES AND NON-TOXIC LPS
WO2007095316A2 (en) *	2006-02-15	2007-08-23	Coley Pharmaceutical Gmbh	Compositions and methods for oligonucleotide formulations
WO2007143582A2 (en) *	2006-06-05	2007-12-13	Baylor College Of Medicine	Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
MX2009003398A (es)	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US8377898B2 (en) *	2006-10-12	2013-02-19	Idera Pharmaceuticals, Inc.	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
JP2010536907A (ja)	2007-08-31	2010-12-02	ニューリミューンセラピューティクスエイジー	患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
CN101820908A (zh) *	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物
WO2009105641A2 (en) *	2008-02-20	2009-08-27	New York University	Preventing and treating amyloid-beta deposition by stimulation of innate immunity
ES2560782T3 (es)	2008-11-04	2016-02-22	Index Pharmaceuticals Ab	Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
BRPI0923225A2 (pt)	2008-12-02	2016-10-04	Chiralgen Ltd	metodo para sintese de acidos nucleicos modificados no atomo de fosforo
KR101856462B1 (ko)	2009-03-25	2018-05-10	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
EP2451461A4 (en)	2009-07-06	2013-05-29	Ontorii Inc	NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
JP2013520498A (ja)	2010-02-25	2013-06-06	デュークユニバーシティー	防御的抗ｈｉｖ−１抗体の産生を誘導する方法
NZ729044A (en)	2010-09-09	2020-07-31	Pfizer	4-1bb binding molecules
DK2620428T3 (da)	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
WO2012084991A1 (en) *	2010-12-21	2012-06-28	Index Pharmaceuticals Ab	Biologically active oligonucleotides capable of modulating the immune system ii
EP2471926A3 (en)	2010-12-30	2012-07-11	Intervet International BV	Immunostimulatory oligodeoxynucleotides
CN107365339A (zh)	2011-07-19	2017-11-21	波涛生命科学有限公司	合成官能化核酸的方法
EP2858722B8 (en)	2012-06-08	2018-02-21	Aduro BioTech, Inc.	Compostions and methods for cancer immunotherapy
AR091569A1 (es)	2012-06-28	2015-02-11	Intervet Int Bv	Receptores de tipo toll
WO2014010250A1 (en)	2012-07-13	2014-01-16	Chiralgen, Ltd.	Asymmetric auxiliary group
DK2872147T3 (da)	2012-07-13	2023-02-20	Wave Life Sciences Ltd	Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) *	2012-07-13	2015-04-29	Shin Nippon Biomedical Lab Ltd	Chiral nucleic acid adjuvant
SG11201502796RA (en)	2012-12-13	2015-05-28	Aduro Biotech Inc	Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
DK3896088T3 (da)	2013-02-20	2025-09-29	Innate Pharma	Behandling af perifert t-cellelymfom
JP2016524593A (ja)	2013-04-29	2016-08-18	メモリアルスローン−ケタリングキャンサーセンター	セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) *	2013-05-03	2019-11-12	加利福尼亚大学董事会	I型干扰素的环状二核苷酸诱导
CU24377B1 (es)	2013-05-18	2018-12-05	Aduro Biotech Inc	Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en)	2013-05-18	2019-03-27	Aduro Biotech, Inc.	Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US20160130346A1 (en)	2013-05-29	2016-05-12	Institut National De La Sante Et De La Recherche Medicale	Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
US10176292B2 (en)	2013-07-31	2019-01-08	Memorial Sloan-Kettering Cancer Center	STING crystals and modulators
WO2015048635A1 (en)	2013-09-27	2015-04-02	Duke University	Mper-liposome conjugates and uses thereof
EP3095459A4 (en) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095461A4 (en) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108046A1 (ja) *	2014-01-15	2015-07-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3094728B1 (en)	2014-01-16	2022-03-09	Wave Life Sciences Ltd.	Chiral design
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016044839A2 (en)	2014-09-19	2016-03-24	The Board Of Regents Of The University Of Texas System	Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016081911A2 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
HUE053145T2 (hu)	2014-12-31	2021-06-28	Checkmate Pharmaceuticals Inc	Kombinált tumor immunterápia
EP3301179B1 (en) *	2015-07-09	2019-06-05	National Institute for Materials Science	Immunostimulating oligonucleotide complex
US11013757B2 (en) *	2016-06-03	2021-05-25	Wave Life Sciences Ltd.	Oligonucleotides, compositions and methods thereof
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
US12460208B2 (en)	2017-04-18	2025-11-04	Parr Biotechnology Co., Ltd.	Immunomodulatory polynucleotides and uses thereof
CN108728444A (zh) *	2017-04-18	2018-11-02	长春华普生物技术股份有限公司	免疫调节性多核苷酸及其应用
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
CN111511762B (zh)	2017-08-21	2025-05-06	天演药业公司	抗cd137分子及其用途
PL3700564T3 (pl) *	2017-12-15	2026-02-23	Elanco Animal Health Gmbh	Kompozycje immunostymulujące
WO2019148444A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt)	2018-04-09	2021-01-12	Checkmate Pharmaceuticals	Empacotamento de oligonucleotídeos em partículas similares a vírus
JP2021521140A (ja) *	2018-04-12	2021-08-26	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en)	2018-05-11	2019-11-14	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
AU2019274654B2 (en)	2018-05-23	2023-07-20	Pfizer Inc.	Antibodies specific for CD3 and uses thereof
US11525010B2 (en)	2018-05-23	2022-12-13	Pfizer Inc.	Antibodies specific for GUCY2c and uses thereof
WO2020128893A1 (en)	2018-12-21	2020-06-25	Pfizer Inc.	Combination treatments of cancer comprising a tlr agonist
JP7369297B2 (ja)	2019-12-17	2023-10-25	ファイザー・インク	Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
US12686870B2 (en)	2020-01-10	2026-07-21	Sbi Biotech Co., Ltd.	TLR9 agonists
EP4149547A4 (en)	2020-05-13	2024-08-14	Adagene AG	Compositions and methods for treating cancer
WO2022034555A1 (en) *	2020-08-13	2022-02-17	Janssen Biopharma, Inc.	Polynucleotide constructs and uses thereof
JP2022161046A (ja) *	2021-04-08	2022-10-21	グラドコフ・アレクセイ	Ｎｋ細胞能力アップ方法

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
EP0092574B1 (en)	1981-10-23	1992-04-29	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and methods of making same
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JPH0874B2 (ja)	1990-07-27	1996-01-10	アイシス・ファーマシューティカルス・インコーポレーテッド	遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
JP3507486B2 (ja)	1991-03-15	2004-03-15	アムジエン・インコーポレーテツド	顆粒球コロニー刺激因子の肺内投与
JPH08502723A (ja)	1992-07-27	1996-03-26	ハイブライドンインコーポレイテッド	オリゴヌクレオチド・アルキルホスホノチオエート
DE4321946A1 (de)	1993-07-01	1995-01-12	Hoechst Ag	Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US6605708B1 (en)	1993-07-28	2003-08-12	Hybridon, Inc.	Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5859231A (en)	1993-09-03	1999-01-12	Duke University	Synthesis of oligonucleotides with boranophosphonate linkages
DE4338704A1 (de)	1993-11-12	1995-05-18	Hoechst Ag	Stabilisierte Oligonucleotide und deren Verwendung
US5646126A (en) *	1994-02-28	1997-07-08	Epoch Pharmaceuticals	Sterol modified oligonucleotide duplexes having anticancer activity
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995026204A1 (en) *	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US5451569A (en)	1994-04-19	1995-09-19	Hong Kong University Of Science And Technology R & D Corporation Limited	Pulmonary drug delivery system
US5658738A (en)	1994-05-31	1997-08-19	Becton Dickinson And Company	Bi-directional oligonucleotides that bind thrombin
US5696248A (en)	1994-06-15	1997-12-09	Hoechst Aktiengesellschaft	3'-modified oligonucleotide derivatives
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030050263A1 (en)	1994-07-15	2003-03-13	The University Of Iowa Research Foundation	Methods and products for treating HIV infection
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
AU713040B2 (en)	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
DE19502912A1 (de)	1995-01-31	1996-08-01	Hoechst Ag	G-Cap Stabilisierte Oligonucleotide
US5968909A (en)	1995-08-04	1999-10-19	Hybridon, Inc.	Method of modulating gene expression with reduced immunostimulatory response
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US5856462A (en)	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
WO1998016247A1 (en)	1996-10-11	1998-04-23	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
CA2281838A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (en)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Processes for preparing nucleic acid constructs
US20040006034A1 (en)	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) *	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE408422T1 (de)	1997-07-03	2008-10-15	Donald E Macfarlane	Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
PT1009413E (pt)	1997-09-05	2007-05-31	Univ California	Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
JPH11209289A (ja)	1998-01-22	1999-08-03	Taisho Pharmaceut Co Ltd	粘膜免疫誘起剤
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2326823A1 (en)	1998-04-20	1999-10-28	Ribozyme Pharmaceuticals, Inc.	Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
EP1077708A1 (en)	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
AU760795B2 (en)	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
JP2002521489A (ja)	1998-07-27	2002-07-16	ユニバーシティオブアイオワリサーチファウンデーション	ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
HK1042706A1 (zh)	1998-08-03	2002-08-23	东卡罗来纳大学	低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
WO2000014217A2 (en)	1998-09-03	2000-03-16	Coley Pharmaceutical Gmbh	G-motif oligonucleotides and uses thereof
US6207819B1 (en)	1999-02-12	2001-03-27	Isis Pharmaceuticals, Inc.	Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (en)	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynucleotide and its use to induce an immune response
EP1177439B1 (en)	1999-04-29	2004-09-08	Coley Pharmaceutical GmbH	Screening for immunostimulatory dna functional modifiers
CA2412345A1 (en)	1999-06-16	2000-12-21	University Of Iowa Research Foundation	Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
DE60017259T2 (de)	1999-08-13	2005-12-08	Hybridon, Inc., Cambridge	Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
WO2001022972A2 (en)	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Immunostimulatory nucleic acids
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
IL148844A0 (en) *	1999-09-27	2002-09-12	Coley Pharm Group Inc	Methods related to immunostimulatory nucleic acid-induced interferon
WO2001051500A1 (en)	2000-01-14	2001-07-19	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en)	2000-01-20	2001-11-22	Mccluskie Michael J.	Immunostimulatory nucleic acids for inducing a Th2 immune response
WO2001055370A2 (en)	2000-01-26	2001-08-02	Hybridon, Inc.	MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en)	2000-03-03	2002-10-24	Bratzler Robert L.	Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en)	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) *	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
CA2404041A1 (en)	2000-03-28	2001-10-04	The Regents Of The University Of California	Methods for increasing a cytotoxic t lymphocyte response in vivo
DE10016079A1 (de) *	2000-03-31	2001-10-04	Alstom Power Nv	Verfahren zum Entfernen von Kohlendioxid aus dem Abgas einer Gasturbinenanlage sowie Vorrichtung zur Durchführung des Verfahrens
HU228264B1 (en)	2000-06-08	2013-02-28	Intercell Ag	Immunostimulatory oligodeoxynucleotides
EP1296714B1 (en)	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20020165178A1 (en)	2000-06-28	2002-11-07	Christian Schetter	Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en)	2000-08-01	2002-12-26	Bratzler Robert L.	Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en)	2000-09-07	2002-07-11	Bratzler Robert L.	Nucleic acids for the prevention and treatment of sexually transmitted diseases
EP1366077B1 (en)	2000-09-15	2011-05-25	Coley Pharmaceutical GmbH	PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
EP2292632A3 (en)	2000-09-26	2012-07-25	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2002069369A2 (en)	2000-12-08	2002-09-06	Coley Pharmaceutical Gmbh	Cpg-like nucleic acids and methods of use thereof
AU2002248185A1 (en)	2000-12-14	2002-07-16	Coley Pharmaceutical Group, Inc.	Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en)	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7176296B2 (en)	2001-04-30	2007-02-13	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en)	2001-04-30	2006-09-12	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20030129605A1 (en)	2001-05-04	2003-07-10	Dong Yu	Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages
US20040132677A1 (en)	2001-06-21	2004-07-08	Fearon Karen L.	Chimeric immunomodulatory compounds and methods of using the same-IV
KR100985457B1 (ko)	2001-06-21	2010-10-06	다이나박스 테크놀로지 코퍼레이션	키메라 면역조절 화합물 및 그것들의 사용 방법
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en)	2001-08-01	2003-02-17	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
AU2002326561B2 (en)	2001-08-07	2008-04-03	Dynavax Technologies Corporation	Immunomodulatory compositions, formulations, and methods for use thereof
US7354909B2 (en)	2001-08-14	2008-04-08	The United States Of America As Represented By Secretary Of The Department Of Health And Human Services	Method for rapid generation of mature dendritic cells
EA007232B1 (ru)	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
AU2002353783A1 (en)	2001-09-24	2003-04-07	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
WO2003031573A2 (en)	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Toll-like receptor 3 signaling agonists and antagonists
KR20050048539A (ko) *	2001-10-06	2005-05-24	메리얼엘엘씨	ＣｐＧ 제제 및 관련된 방법
AU2002360278A1 (en)	2001-10-12	2003-11-11	Coley Pharmaceutical Gmbh	Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003035836A2 (en)	2001-10-24	2003-05-01	Hybridon Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7276489B2 (en)	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
AU2002366710A1 (en) *	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
NZ535952A (en)	2002-04-04	2009-01-31	Coley Pharm Gmbh	Immunostimulatory G,U-containing oligoribonucleotides
CN101160399A (zh)	2002-04-22	2008-04-09	拜奥尼茨生命科学公司	寡核苷酸组合物及其在调节免疫应答中的应用
WO2003103586A2 (en)	2002-06-05	2003-12-18	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en)	2002-07-17	2004-01-22	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
AU2003278845A1 (en)	2002-09-19	2004-04-08	Coley Pharmaceutical Gmbh	Toll-like receptor 9 (tlr9) from various mammalian species
NZ540098A (en)	2002-10-29	2008-09-26	Coley Pharmaceutical Group Ltd	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
WO2004041183A2 (en)	2002-11-01	2004-05-21	The Regents Of The University Of California	Methods of treating pulmonary fibrotic disorders
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
US7625872B2 (en)	2002-12-23	2009-12-01	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
JP4726630B2 (ja)	2003-01-16	2011-07-20	イデラファーマシューティカルズインコーポレイテッド	修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
EP1608403A2 (en)	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004094671A2 (en)	2003-04-22	2004-11-04	Coley Pharmaceutical Gmbh	Methods and products for identification and assessment of tlr ligands
KR20060012622A (ko)	2003-05-16	2006-02-08	하이브리돈, 인코포레이티드	화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
US7410975B2 (en)	2003-06-20	2008-08-12	Coley Pharmaceutical Group, Inc.	Small molecule toll-like receptor (TLR) antagonists
MXPA06000619A (es)	2003-07-15	2006-04-11	Hybridon Inc	Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
JP4989225B2 (ja)	2003-09-25	2012-08-01	コーリーファーマシューティカルグループ，インコーポレイテッド	核酸親油性接合体
US20050215501A1 (en)	2003-10-24	2005-09-29	Coley Pharmaceutical Group, Inc.	Methods and products for enhancing epitope spreading
NZ546275A (en)	2003-10-30	2009-05-31	Coley Pharm Gmbh	C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050239733A1 (en)	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en)	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
KR101138131B1 (ko)	2003-12-08	2012-04-23	이데라 파마슈티칼즈, 인코포레이티드	작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절
JP2007526253A (ja)	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
CA2557443A1 (en)	2004-03-12	2005-09-29	Hybridon, Inc.	Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
JP2007531746A (ja)	2004-04-02	2007-11-08	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｉｌ−１０応答を誘導するための免疫活性化核酸
WO2006080946A2 (en)	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
US7498425B2 (en)	2004-06-15	2009-03-03	Idera Pharmaceuticals, Inc.	Immunostimulatory oligonucleotide multimers
BRPI0512110A (pt)	2004-06-15	2007-10-23	Idera Pharmaceutical Inc	multìmeros de oligonucleotìdeos imunoestimulatórios
US7283209B2 (en) *	2004-07-09	2007-10-16	Carl Zeiss Smt Ag	Illumination system for microlithography
EP1776105A2 (en)	2004-07-18	2007-04-25	Coley Pharmaceutical Group, Ltd	Methods and compositions for inducing innate immune responses
JP2008506789A (ja)	2004-07-18	2008-03-06	シーエスエル、リミテッド	インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006091915A2 (en)	2005-02-24	2006-08-31	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
EP1874325A2 (en)	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Methods for treating infectious disease exacerbated asthma
AU2006241149A1 (en)	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007008463A2 (en)	2005-07-07	2007-01-18	Coley Pharmaceutical Group, Inc.	Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US7490795B2 (en) *	2005-08-31	2009-02-17	Goodrich Corporation	Aircraft evacuation slide with primary gas relief valve
KR20080047463A (ko)	2005-09-16	2008-05-28	콜리 파마슈티칼 게엠베하	뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
US20090214578A1 (en)	2005-09-16	2009-08-27	Coley Pharmaceutical Gmbh	Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
WO2007038720A2 (en)	2005-09-27	2007-04-05	Coley Pharmaceutical Gmbh	Modulation of tlr-mediated immune responses using adaptor oligonucleotides
US7776834B2 (en)	2005-11-07	2010-08-17	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
WO2007062107A2 (en)	2005-11-25	2007-05-31	Coley Pharmaceutical Gmbh	Immunostimulatory oligoribonucleotides
WO2007095316A2 (en)	2006-02-15	2007-08-23	Coley Pharmaceutical Gmbh	Compositions and methods for oligonucleotide formulations
US8027888B2 (en)	2006-08-31	2011-09-27	Experian Interactive Innovation Center, Llc	Online credit card prescreen systems and methods
WO2008033432A2 (en)	2006-09-12	2008-03-20	Coley Pharmaceutical Group, Inc.	Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
US20100189772A1 (en)	2006-09-27	2010-07-29	Coley Pharmaceutical Group, Inc	Compositions of TLR ligands and antivirals
MX2009003398A (es)	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
EP2104738A2 (en)	2006-10-26	2009-09-30	Coley Pharmaceuticals GmbH	Oligoribonucleotides and uses thereof
US20090142362A1 (en)	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
BRPI0811621A2 (pt)	2007-05-17	2014-10-21	Coley Pharm Group Inc	Oligonucleotídeos de classe a com potência imunoestimuladora, composição contendo os mesmos e uso da referida composição
CN101820908A (zh)	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物

2003
- 2003-08-15 AR ARP030102974A patent/AR040996A1/es unknown
- 2003-08-18 TW TW092122592A patent/TW200412981A/zh unknown
- 2003-08-18 SV SV2003001602A patent/SV2008001602A/es unknown
- 2003-08-19 HU HUE03788643A patent/HUE030347T2/en unknown
- 2003-08-19 NZ NZ560722A patent/NZ560722A/en not_active IP Right Cessation
- 2003-08-19 ES ES10185869.4T patent/ES2634328T3/es not_active Expired - Lifetime
- 2003-08-19 MX MXPA05002014A patent/MXPA05002014A/es active IP Right Grant
- 2003-08-19 BR BRPI0313414-8A patent/BR0313414A/pt active Search and Examination
- 2003-08-19 US US10/644,052 patent/US8283328B2/en not_active Expired - Fee Related
- 2003-08-19 KR KR1020087001536A patent/KR20080011247A/ko not_active Withdrawn
- 2003-08-19 WO PCT/US2003/025935 patent/WO2004016805A2/en not_active Ceased
- 2003-08-19 KR KR1020057002841A patent/KR100969727B1/ko not_active Expired - Fee Related
- 2003-08-19 ES ES03788643.9T patent/ES2600553T3/es not_active Expired - Lifetime
- 2003-08-19 PE PE2003000841A patent/PE20040900A1/es not_active Application Discontinuation
- 2003-08-19 PT PT101858694T patent/PT2290078T/pt unknown
- 2003-08-19 PL PL414814A patent/PL232260B1/pl unknown
- 2003-08-19 OA OA1200500045A patent/OA12906A/en unknown
- 2003-08-19 RS YUP-2005/0126A patent/RS20050126A/sr unknown
- 2003-08-19 HU HUE10185869A patent/HUE035336T2/en unknown
- 2003-08-19 UY UY27945A patent/UY27945A1/es not_active Application Discontinuation
- 2003-08-19 DK DK03788643.9T patent/DK1538904T3/en active
- 2003-08-19 AU AU2003259916A patent/AU2003259916B2/en not_active Ceased
- 2003-08-19 NZ NZ538001A patent/NZ538001A/en not_active IP Right Cessation
- 2003-08-19 PL PL375398A patent/PL227938B1/pl unknown
- 2003-08-19 EP EP10185869.4A patent/EP2290078B1/en not_active Expired - Lifetime
- 2003-08-19 DK DK10185869.4T patent/DK2290078T3/en active
- 2003-08-19 PE PE2008000498A patent/PE20081155A1/es not_active Application Discontinuation
- 2003-08-19 EP EP03788643.9A patent/EP1538904B1/en not_active Expired - Lifetime
- 2003-08-19 CA CA2493753A patent/CA2493753C/en not_active Expired - Fee Related
- 2003-08-19 SI SI200332533T patent/SI2290078T1/sl unknown
- 2003-08-19 JP JP2005502069A patent/JP5414961B2/ja not_active Expired - Fee Related
- 2003-08-19 PT PT37886439T patent/PT1538904T/pt unknown
2005
- 2005-01-18 IL IL166376A patent/IL166376A/en active IP Right Grant
- 2005-03-18 NO NO20051469A patent/NO20051469L/no not_active Application Discontinuation
- 2005-03-18 MA MA28164A patent/MA27468A1/fr unknown
- 2005-03-18 EC EC2005005687A patent/ECSP055687A/es unknown
2006
- 2006-10-04 US US11/542,845 patent/US8304396B2/en not_active Expired - Fee Related
2009
- 2009-12-23 AU AU2009251186A patent/AU2009251186B2/en not_active Ceased
2010
- 2010-07-12 JP JP2010158316A patent/JP2011004746A/ja active Pending

Also Published As

Publication number	Publication date
EP2290078A3 (en)	2013-02-13
EP1538904A2 (en)	2005-06-15
KR100969727B1 (ko)	2010-07-13
CA2493753C (en)	2014-07-08
AU2003259916A1 (en)	2004-03-03
DK1538904T3 (en)	2016-11-21
UY27945A1 (es)	2004-03-31
AU2003259916B2 (en)	2010-01-21
PE20081155A1 (es)	2008-08-15
AU2009251186B2 (en)	2013-05-30
OA12906A (en)	2006-10-13
ES2634328T3 (es)	2017-09-27
JP2011004746A (ja)	2011-01-13
TW200412981A (en)	2004-08-01
AU2009251186A1 (en)	2010-01-28
PT2290078T (pt)	2017-07-31
HUE030347T2 (en)	2017-05-29
CA2493753A1 (en)	2004-02-26
EP2290078B1 (en)	2017-04-26
US8283328B2 (en)	2012-10-09
KR20080011247A (ko)	2008-01-31
BR0313414A (pt)	2007-07-31
SI2290078T1 (sl)	2017-08-31
AR040996A1 (es)	2005-04-27
DK2290078T3 (en)	2017-07-31
PL375398A1 (pl)	2005-11-28
NZ538001A (en)	2008-05-30
WO2004016805A3 (en)	2005-02-17
WO2004016805A2 (en)	2004-02-26
PE20040900A1 (es)	2004-12-29
EP1538904B1 (en)	2016-07-27
JP2006508693A (ja)	2006-03-16
ES2600553T3 (es)	2017-02-09
IL166376A (en)	2012-10-31
PL227938B1 (pl)	2018-01-31
US8304396B2 (en)	2012-11-06
KR20050034738A (ko)	2005-04-14
ECSP055687A (es)	2005-05-30
US20070224210A1 (en)	2007-09-27
EP2290078A2 (en)	2011-03-02
PL232260B1 (pl)	2019-05-31
MA27468A1 (fr)	2005-08-01
WO2004016805A9 (en)	2004-08-19
EP1538904A4 (en)	2008-03-05
JP5414961B2 (ja)	2014-02-12
RS20050126A (sr)	2007-06-04
NZ560722A (en)	2009-10-30
PT1538904T (pt)	2016-11-08
MXPA05002014A (es)	2005-10-19
US20050059619A1 (en)	2005-03-17
SV2008001602A (es)	2008-02-27
IL166376A0 (en)	2006-01-16
PL414814A1 (pl)	2016-03-14
HUE035336T2 (en)	2018-05-02

Legal Events

Date	Code	Title	Description
2013-03-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
PL375398A1 (pl)	2005-11-28	Immunostymulujące kwasy nukleinowe
ATE426412T1 (de)	2009-04-15	Adjuvante influenza-vakzine
WO2004053104A3 (en)	2005-12-15	5’ cpg nucleic acids and methods of use
ATE315405T1 (de)	2006-02-15	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
MY137619A (en)	2009-02-27	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004030608A3 (en)	2005-03-10	Nanoemulsion vaccines
DE60335350D1 (de)	2011-01-27	Adjuvantien für dns impstoffe basierend auf imidazochinoline
WO2004098491A3 (en)	2007-02-22	METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
ATE292638T1 (de)	2005-04-15	Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside
NO20092023L (no)	2009-06-23	Oligoribonuleotider og anvendelser derav
NO20052426L (no)	2005-05-19	Fremgangsmater for vaksinasjon mot malaria
ATE463575T1 (de)	2010-04-15	Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
DE60037900D1 (de)	2008-03-13	Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
DE60036698D1 (de)	2007-11-22	Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
WO2004005476A3 (en)	2004-05-21	Nucleic acid compositions for stimulating immune responses
ATE392216T1 (de)	2008-05-15	Mycobakterieller impfstoff
WO2000050073A3 (en)	2001-02-22	Caulobacter lps immunoadjuvant
WO2005081847A3 (en)	2005-12-22	Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
CY1107845T1 (el)	2013-06-19	Γενετικα εμβολια με ανοσοενισχυτικο
TNSN05052A1 (en)	2007-05-14	Immunostimulatory nucleic acids
SG147465A1 (en)	2008-11-28	Vaccine
AR022758A1 (es)	2002-09-04	Vacunas
BR0207447A (pt)	2004-06-29	Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina
NO20051840L (no)	2005-06-16	IHNV G-protein til immunstimulering.
SG166673A1 (en)	2010-12-29	Immunostimulatory nucleic acids